WO1998029069B1 - Method for changing the refractive power of an eye - Google Patents
Method for changing the refractive power of an eyeInfo
- Publication number
- WO1998029069B1 WO1998029069B1 PCT/US1997/023794 US9723794W WO9829069B1 WO 1998029069 B1 WO1998029069 B1 WO 1998029069B1 US 9723794 W US9723794 W US 9723794W WO 9829069 B1 WO9829069 B1 WO 9829069B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- refractive power
- eye
- change
- composition according
- composition
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract 6
- 150000003431 steroids Chemical class 0.000 claims abstract 4
- 210000002469 Basement Membrane Anatomy 0.000 claims abstract 2
- 230000036040 emmetropia Effects 0.000 claims abstract 2
- 229960001209 CLONIXIN Drugs 0.000 claims 2
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N Clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 claims 2
- 229960004369 Flufenamic Acid Drugs 0.000 claims 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 230000003110 anti-inflammatory Effects 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- RUAYXHSDAMWEDR-UHFFFAOYSA-N 2-(4-tert-butylphenyl)acetic acid Chemical compound CC(C)(C)C1=CC=C(CC(O)=O)C=C1 RUAYXHSDAMWEDR-UHFFFAOYSA-N 0.000 claims 1
- SNUBSRMFCPAKSI-UHFFFAOYSA-N 2-(dimethylamino)ethanol;2-(4-phenylphenyl)butanoic acid Chemical compound CN(C)CCO.C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 SNUBSRMFCPAKSI-UHFFFAOYSA-N 0.000 claims 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 210000004087 Cornea Anatomy 0.000 claims 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 1
- 229950007979 FLUFENISAL Drugs 0.000 claims 1
- 229960001419 Fenoprofen Drugs 0.000 claims 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 claims 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N Fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 229960000905 Indomethacin Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N Loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- 229950008948 Namoxyrate Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960001487 RIMEXOLONE Drugs 0.000 claims 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N Rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 1
- 229960004492 Suprofen Drugs 0.000 claims 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- -1 alkylofenac Chemical compound 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- 229960001048 fluorometholone Drugs 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 claims 1
- 229950009183 ibufenac Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- 229960002373 loxoprofen Drugs 0.000 claims 1
- 229960001011 medrysone Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- 206010020675 Hypermetropia Diseases 0.000 abstract 1
- 208000001491 Myopia Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004305 hyperopia Effects 0.000 abstract 1
- 201000006318 hyperopia Diseases 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Abstract
A method provides for changing the refractive power of an eye, and includes the step of selecting a dioptic correction for an eye without compromise for regression of refractive power due to biological response to a change in corneal profile, changing the corneal profile of the eye in order to change the refractive power of the eye to the selected dioptic, (e.g. by laser of surgical procedures) and limiting regression in corneal profile due to the undesired biological response at about the selected diopter by applying to the corneal composition comprising an agent for controlling the biological response. The agent comprised in the composition may be a steroid, a non-steroidal anti-inflammatory agent or a basement membrane component. The change in the refractive power is intended to achieve emmetropia. The method of the present invention allows the correction of refractive/focusing disorders of the eye such as myopia, hyperopia, (a)stigmatism (etc.).
Claims
Claim 1. A composition comprising an agent for controlling biological response having properties enabling a change in the refractive power of an eye by selecting a dioptic correction for an eye without compromise for regression of refractive power due to biological response to a change in corneal profile, changing the corneal profile of the eye in order to change the refractive power of the eye to the selected dioptic, and limiting regression in corneal profile in order to maintain the refractive power to about the selective diopter by applying to the cornea the composition before changing the corneal profile.
Claim 2. The method according to claim 1 wherein the changing of the corneal profile includes a change in the refractive power of at least six diopters.
Claim 3. The method according to claim 2 wherein the change in the refractive power causes emmetropia.
Claim 4. The composition according to claim 1 wherein said agent comprises a steroid.
Claim 5. The composition according to claim 4 wherein the steroid is present at a concentration of about 0.1 to about 4.0 wt. %.
Claim 6. The composition according to claim 5 wherein the steroid is selected from the group consisting of decamethasone, prednisolone, prednisone, fluorometholone, rimexolone, medrysone, betamethasone, triamcinolone and hydrocortisone. 31
Claim 7. The composition according to claim 1 wherein said agent comprises a basement membrane component.
Claim 8. The composition according to claim 1 wherein said agent comprises a non-steroidal antiinflammatory.
Claim 9. The composition according to claim 8 wherein the non-steroidal antiinflammatory is selected from the group consisting of flurbiprofen, suprofen, mefenamic acid, flufenamic acid, clonixin, flufenamic acid, clonixin, flufenisal, ibufenac, 4-(t-butyl) benzeneacetic acid, ibuprofen, alkylofenac, fenoprofen, naproxen, indomethacin, tol etin, ketoprofen, namoxyrate, ketorolac and loxoprofen.
STATEMENT UNDER ARTICLE 19
In response to an International Search Report, mailed 8 July 1998, the Applicant has limited the scope of the claims to the composition of the invention. No new matter is added by this amendment as the new claims correspond to originally filed claims as indicated in the letter accompanying the replacement pages. The present amendment replacing claims does not affect the original description or the original drawings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU58059/98A AU5805998A (en) | 1997-01-02 | 1997-12-29 | Method for changing the refractive power of an eye |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77803297A | 1997-01-02 | 1997-01-02 | |
| US08/778,032 | 1997-01-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998029069A2 WO1998029069A2 (en) | 1998-07-09 |
| WO1998029069A3 WO1998029069A3 (en) | 1998-10-08 |
| WO1998029069B1 true WO1998029069B1 (en) | 1998-11-12 |
Family
ID=25112096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/023794 WO1998029069A2 (en) | 1997-01-02 | 1997-12-29 | Method for changing the refractive power of an eye |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5805998A (en) |
| WO (1) | WO1998029069A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002211D0 (en) * | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| AU2002232437A1 (en) | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic lubricating solution adapted for use in lasik surgery |
| US6878694B2 (en) | 2000-12-20 | 2005-04-12 | Alcon, Inc. | Ophthalmic irrigating solution adapted for use in lasik surgery |
| US20080139671A1 (en) * | 2006-12-07 | 2008-06-12 | Priavision, Inc. | Method and material for in situ corneal structural augmentation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3831604A (en) * | 1973-04-18 | 1974-08-27 | C Neefe | Method of reshaping the cornea |
| CA1016435A (en) * | 1973-06-28 | 1977-08-30 | Charles W. Neefe | Concave mold for reshaping the cornea to eliminate refractive error |
| US4983580A (en) * | 1986-04-04 | 1991-01-08 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
| WO1989004172A1 (en) * | 1987-11-09 | 1989-05-18 | Chiron Ophthalmics Inc. | Wound healing composition and method |
| US4973466A (en) * | 1988-06-21 | 1990-11-27 | Chiron Ophthalmics, Inc. | Wound-healing dressings and methods |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| US5036046A (en) * | 1988-10-12 | 1991-07-30 | Eye Research Institute Of Retina Foundation, Inc. | Method for enhancing healing of corneal endothelial wounds |
| WO1993006856A1 (en) * | 1991-10-11 | 1993-04-15 | Mark Cedric Gillies | Treating ophthalmic fibrosis using interferon-alpha |
| US5270051A (en) * | 1991-10-15 | 1993-12-14 | Harris Donald H | Enzyme-orthokeratology |
| WO1994005322A1 (en) * | 1992-09-04 | 1994-03-17 | Summit Technology, Inc. | A plasmin activity reducing agent for treating a superficial corneal ablation wound and related screening method |
| CA2159706A1 (en) * | 1994-02-04 | 1995-08-10 | Peter John Mcdonnell | Method for preventing keratocyte loss |
-
1997
- 1997-12-29 AU AU58059/98A patent/AU5805998A/en not_active Abandoned
- 1997-12-29 WO PCT/US1997/023794 patent/WO1998029069A2/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5401509A (en) | Pharmaceutical compositions and methods of treatment of the cornea in conjunction with laser irradiation | |
| US4939135A (en) | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation | |
| US5124392A (en) | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation | |
| US5624893A (en) | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation | |
| JP3300855B2 (en) | Eye treatment probe | |
| Price | Air lamellar keratoplasty | |
| US20060241751A1 (en) | Corneal onlays and methods of producing same | |
| EP0238636A1 (en) | Method of manufacture and implantation of corneal inlays | |
| AU3041289A (en) | "spare parts" for ophthalmic surgical procedures | |
| WO2006113563A1 (en) | Bifocal implant and method for altering the refractive properties of the eye | |
| AU2673292A (en) | Reprofiling of synthetic lenticules | |
| WO1998029069B1 (en) | Method for changing the refractive power of an eye | |
| Wilson et al. | Corrective measures for myopia | |
| Thoft | Conjunctival transplantation as an alternative to keratoplasty | |
| WO1998029069A3 (en) | Method for changing the refractive power of an eye | |
| WO1997015298A1 (en) | Combination of ltd, receptor antagonists with glucocorticosteroids | |
| RU2348384C1 (en) | Method of cornea surface reconstruction in patients suffering from monocular burn leukomas | |
| Stainer et al. | Vitreous wick syndrome following a corneal relaxing incision | |
| Ober et al. | Traumatic retinopathy in Stargardt's disease | |
| SU1071300A1 (en) | Method of correction of myopia and myopic astigmatism | |
| RU2002105933A (en) | Method for surgical correction of mild residual myopia and mild residual myopic astigmatism after Lazik surgery | |
| Haselwood et al. | The Castroviejo square graft | |
| Kaufman | Surgical approaches to corneal wound healing | |
| RU2197210C2 (en) | Method for correcting ametropia | |
| Kanjanabuch et al. | A case of steroid-resistance FSGA with podocin mutation |